Nivolumab (Opdivo) for melanoma, adjuvant

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Regimen in use at


Study Evidence Comparator Efficacy 12-month recurrence-free survival (RFS) Comparator RFS
Weber et al. 2017 (Checkmate 238) Phase 3 (E-RT-switch-ic) Ipilimumab Superior RFS 70.5% overall
Stage IIIB or IIIC: 72.3% (95% CI, 67.4 to 76.7)
Stage IV: 63.0% (95% CI, 51.6 to 72.5)
60.8% overall
Stage IIIB or IIIC: 61.6% (95% CI, 56.3 to 66.5)
Stage IV: 57.5% (95% CI, 46 to 67.4)

Preceding treatment

  • Complete resection of stage IIIB, IIIC, or IV melanoma


14-day cycle for up to 26 cycles (1 year)


  1. CheckMate 238: Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA1; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017 Nov 9;377(19):1824-1835. Epub 2017 Sep 10. link to original article contains dosing details in manuscript PubMed